€5.00
+0.20 (+4.17%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MARI.VI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry EyeNCT06262100Change in dry eye symptomsOpen-label · Treatment | Not applicable | Completed | Device: Carragelose | Dry Eye Syndromes | 30 | 2024-07-30actual | 2024-12-09 |
| Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 PatientsNCT04793984Clinical status of subjects as expressed on the WHO-8-Category ordinal scale:Randomized · Double-masked · Treatment | Not applicable | Completed | Device: Carragelose, NaCl | Covid19 | 14 | 2022-07-30actual | 2022-08-29 |
| Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care WorkersNCT04681001Presence of COVID-19 symptoms including symptoms of respiratory viral infection documented in a diaryRandomized · Quadruple-masked · Prevention | Not applicable | Completed | Device: nasal spray | Respiratory Viral Infection, Common Cold, Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19, Corona Virus Disease | 300 | 2021-08-20actual | 2022-08-25 |
| Therapeutic Effect of Tacrosolv in Patients With Allergic RhinoconjunctivitisNCT04532710Total Ocular Symptom ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Eye Drops, Solution in Single-Dose Container | Allergic Conjunctivitis, Allergic Rhinitis | 64 | 2021-05-27actual | 2022-08-25 |
| Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/RhinoconjunctivitisNCT04531358Total Nasal Symptom Score (TNSS)Randomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: nasal spray · Other: no treatment | Allergic Rhinitis, Allergic Rhinoconjunctivitis | 42 | 2020-12-31actual | 2021-02-21 |
| Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.NCT04532762Nasal Congestion Symptom Score (NCSS)Randomized · Quadruple-masked · Treatment | Not applicable | Completed | Device: nasal spray | Allergic Rhinitis, Allergic Rhinoconjunctivitis | 42 | 2020-12-31actual | 2021-02-21 |
| Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold VirusesNCT04533906The primary outcome measure is the iota-carrageenan concentration in saliva.Open-label · Treatment | Not applicable | Completed | Device: Coldamaris lozenges | Common Cold, Viral Infection | 29 | 2020-10-04actual | 2021-01-08 |
| Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal SprayNCT03755557Total Nasal Symptom ScoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Rhinocort, Budesolv · Other: Placebo | Allergic Rhinitis, Allergic Conjunctivitis, Hayfever | 82 | 2019-04-05actual | 2020-10-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19